[go: up one dir, main page]

AR095437A1 - Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso - Google Patents

Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso

Info

Publication number
AR095437A1
AR095437A1 ARP140100983A ARP140100983A AR095437A1 AR 095437 A1 AR095437 A1 AR 095437A1 AR P140100983 A ARP140100983 A AR P140100983A AR P140100983 A ARP140100983 A AR P140100983A AR 095437 A1 AR095437 A1 AR 095437A1
Authority
AR
Argentina
Prior art keywords
fusion proteins
pdgf
vegf
methods
portions
Prior art date
Application number
ARP140100983A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR095437A1 publication Critical patent/AR095437A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)

Abstract

La presente proporciona proteínas de fusión que comprenden porciones de unión PDGF (factor de crecimiento derivado de plaquetas) y VEGF (factor de crecimiento endotelial vascular), y partículas virales recombinantes que codifican las proteínas de fusión. Además, se proporcionan composiciones que comprenden las proteínas de fusión y las partículas virales, así como también métodos para el uso de las mismas. Célula; vector; kit.
ARP140100983A 2013-03-13 2014-03-13 Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso AR095437A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361780914P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
AR095437A1 true AR095437A1 (es) 2015-10-14

Family

ID=50680144

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100983A AR095437A1 (es) 2013-03-13 2014-03-13 Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso

Country Status (26)

Country Link
US (4) US9637534B2 (es)
EP (1) EP2968461B1 (es)
JP (2) JP6561042B2 (es)
KR (1) KR102228921B1 (es)
CN (1) CN105188733B (es)
AR (1) AR095437A1 (es)
AU (2) AU2014243712B2 (es)
BR (1) BR112015022208A8 (es)
CA (1) CA2904623A1 (es)
DK (1) DK2968461T3 (es)
ES (1) ES2933558T3 (es)
FI (1) FI2968461T3 (es)
HR (1) HRP20221447T1 (es)
HU (1) HUE060464T2 (es)
IL (2) IL240950B (es)
LT (1) LT2968461T (es)
MX (1) MX363533B (es)
PL (1) PL2968461T3 (es)
PT (1) PT2968461T (es)
RS (1) RS63820B1 (es)
RU (1) RU2692652C2 (es)
SG (3) SG10201912956YA (es)
SI (1) SI2968461T1 (es)
TW (1) TWI631133B (es)
UY (1) UY35407A (es)
WO (1) WO2014160507A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
SG10201912956YA (en) 2013-03-13 2020-02-27 Genzyme Corp Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof
EP3010525A1 (en) * 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating choroidal neovascularisation
PT3041513T (pt) 2013-09-08 2020-09-07 Kodiak Sciences Inc Conjugados de polímeros zwiteriónicos com fator viii
KR101819135B1 (ko) 2014-03-18 2018-01-18 한국과학기술원 당화 vegf 디코이 수용체 융합 단백질
JP7100425B2 (ja) * 2014-06-28 2022-07-13 コディアック サイエンシーズ インコーポレイテッド デュアルｐｄｇｆ／ｖｅｇｆアンタゴニスト
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
MX2017008643A (es) * 2015-03-11 2018-04-26 Allgenesis Biotherapeutics Inc Proteina de fusion que comprende un dominio de union a ligando de factor de crecimiento endotelial vascular (vegf) y factor de crecimiento derivado de plaquetas (pdgf).
ES2797901T3 (es) 2015-06-28 2020-12-04 Allgenesis Biotherapeutics Inc Proteínas de fusión para la inhibición de angiogénesis
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
AU2017245143B2 (en) 2016-03-30 2024-01-11 Ab Biosciences, Inc. Recombinant intravenous immunoglobulin (rIVIG) compositions and methods for their production and use
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
JP6849390B2 (ja) * 2016-10-28 2021-03-24 花王株式会社 関節のこわばり改善剤
JP7303816B2 (ja) * 2017-10-16 2023-07-05 ビゲネロン ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａａｖベクター
KR102205830B1 (ko) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물
WO2019083171A2 (ko) * 2017-10-26 2019-05-02 주식회사 큐로진생명과학 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물
CN111406071B (zh) * 2017-11-16 2024-01-16 成都硕德药业有限公司 Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途
US11548931B2 (en) 2017-11-16 2023-01-10 Xl-Protein Gmbh PASylated VEGFR/PDGFR fusion proteins and their use in therapy
EP4495136A3 (en) * 2018-01-26 2025-04-23 The Regents of the University of California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
AU2020396699B2 (en) * 2019-12-04 2024-07-18 Cdmogen Co., Ltd Composition for treating diabetic retinopathy, comprising rAAV containing soluble VEGFR-1 variant cDNA
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
CN113105558A (zh) * 2021-04-01 2021-07-13 芜湖英特菲尔生物制品产业研究院有限公司 一种酿酒酵母表达人rPDGF-HSA融合蛋白及其标准品的制备方法
AU2022294194A1 (en) * 2021-06-18 2024-01-04 Ikarovec Limited Retinal disorders
WO2023199951A1 (ja) * 2022-04-13 2023-10-19 株式会社セルージョン 抗ｖｅｇｆ機能を有する多能性幹細胞及びその分化細胞
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
KR102764987B1 (ko) * 2022-08-02 2025-02-12 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도
WO2025033876A1 (ko) * 2023-08-04 2025-02-13 주식회사 파노로스바이오사이언스 변형된 융합 단백질과 scFv의 결합체 및 이의 용도
WO2025042305A1 (ru) * 2023-08-18 2025-02-27 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующпя слитый белок pdgfra-hfc

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4952515A (en) 1987-05-22 1990-08-28 Polymer Technology International Corp. Method of detection using a test strip having a non particulate dialyzed polymer layer
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
AU1411092A (en) 1991-01-31 1992-09-07 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU781958C (en) 1999-08-09 2006-03-30 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
US20030181531A1 (en) 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
AU2003218168A1 (en) 2002-03-15 2003-09-29 University Of Southern California Ophthalmic solutions for delivery of expression vectors
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
PL1804835T3 (pl) 2004-09-13 2010-11-30 Genzyme Corp Konstrukty multimeryczne
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
DE102005020510A1 (de) 2005-04-29 2006-11-09 Basf Ag Verbundelement, insbesondere Fensterscheibe
US8216575B2 (en) * 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
WO2009105669A2 (en) * 2008-02-20 2009-08-27 Genzyme Corporation Angiogenesis inhibition
ES2456296T3 (es) * 2008-03-27 2014-04-21 Zymogenetics, Inc. Composiciones y procedimientos para inhibir PDGFR beta y VEGF-A
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
CN102311502B (zh) * 2010-07-10 2013-12-25 成都康弘生物科技有限公司 一种抑制血管新生或生长的融合蛋白及其医疗应用
AU2011336592A1 (en) * 2010-12-02 2013-07-11 Neurotech Usa, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
SG10201912956YA (en) 2013-03-13 2020-02-27 Genzyme Corp Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof

Also Published As

Publication number Publication date
HK1220618A1 (en) 2017-05-12
SG11201506802SA (en) 2015-09-29
JP6561042B2 (ja) 2019-08-14
UY35407A (es) 2014-10-31
CN105188733B (zh) 2020-05-08
ES2933558T3 (es) 2023-02-10
BR112015022208A2 (pt) 2017-10-10
SG10201707501TA (en) 2017-10-30
PL2968461T3 (pl) 2023-01-30
US20140315804A1 (en) 2014-10-23
KR102228921B1 (ko) 2021-03-16
HUE060464T2 (hu) 2023-03-28
PT2968461T (pt) 2022-12-26
RS63820B1 (sr) 2023-01-31
US20190345223A1 (en) 2019-11-14
KR20150126923A (ko) 2015-11-13
US9637534B2 (en) 2017-05-02
HRP20221447T1 (hr) 2023-01-20
JP2019123711A (ja) 2019-07-25
AU2018278902A1 (en) 2019-01-03
FI2968461T3 (fi) 2023-01-13
US20170342127A1 (en) 2017-11-30
IL240950A0 (en) 2015-11-30
AU2014243712A1 (en) 2015-10-15
SI2968461T1 (sl) 2023-01-31
WO2014160507A1 (en) 2014-10-02
LT2968461T (lt) 2022-12-27
CN105188733A (zh) 2015-12-23
CA2904623A1 (en) 2014-10-02
US20220064262A1 (en) 2022-03-03
BR112015022208A8 (pt) 2018-01-23
IL266715A (en) 2019-07-31
EP2968461B1 (en) 2022-09-21
AU2014243712B2 (en) 2018-09-13
RU2692652C2 (ru) 2019-06-25
IL240950B (en) 2019-06-30
MX2015011951A (es) 2016-04-07
TW201506038A (zh) 2015-02-16
RU2015142999A (ru) 2017-04-17
JP2016513669A (ja) 2016-05-16
DK2968461T3 (da) 2022-12-19
MX363533B (es) 2019-03-27
EP2968461A1 (en) 2016-01-20
US10183983B2 (en) 2019-01-22
US11084864B2 (en) 2021-08-10
TWI631133B (zh) 2018-08-01
SG10201912956YA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
AR095437A1 (es) Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso
IL273886A (en) B cell maturation antigen binding proteins
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
MX382518B (es) Antigenos de citomegalovirus y su uso.
CL2017002454A1 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
AR091024A1 (es) Anticuerpos capaces de unirse al factor xi de coagulacion y/o a su forma activada, factor xia, y sus usos
MX2017011679A (es) Polipeptidos de transposasa y sus usos.
EA202090216A2 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
CL2015002669A1 (es) Polipeptidos que contienen región fc aglicosilada
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
MX365612B (es) Polipeptidos de factor x modificados y usos de los mismos.
EA201791918A1 (ru) Модификация белков клеток-хозяев
EA201391523A1 (ru) Композиции и способы для переноса энергии митохондрий аутологичных герминативных клеток
UY34527A (es) ?composiciones, métodos y kits para la preparación de proteínas recombinantes sialiladas?.
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
MX379312B (es) Anticuerpos especificos para fcrn.
MX2015012168A (es) Expansión de celulas madre adultas in vitro.
MX2015014424A (es) Construcciones de proteinas mitocondriales y sus usos.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
WO2015041809A3 (en) Small molecule cellular reprogramming to generate neuronal cells
MX2016002208A (es) Polipeptidos de union a c5.
AR095268A1 (es) ANTICUERPOS HUMANOS QUE SE UNEN AL FACTOR a DE LA NECROSIS (TNF-a) HUMANO Y MÉTODOS PARA PREPARARLOS

Legal Events

Date Code Title Description
FB Suspension of granting procedure